254 related articles for article (PubMed ID: 28087216)
1. Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures.
Tetsunaga T; Tetsunaga T; Nishida K; Tanaka M; Sugimoto Y; Takigawa T; Takei Y; Ozaki T
J Orthop Sci; 2017 Mar; 22(2):230-236. PubMed ID: 28087216
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
[No Abstract] [Full Text] [Related]
3. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
[TBL] [Abstract][Full Text] [Related]
5. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study.
Iwata A; Kanayama M; Oha F; Hashimoto T; Iwasaki N
BMC Musculoskelet Disord; 2017 Apr; 18(1):148. PubMed ID: 28388910
[TBL] [Abstract][Full Text] [Related]
6. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Doria C; Mosele GR; Solla F; Maestretti G; Balsano M; Scarpa RM
Minerva Urol Nefrol; 2017 Jun; 69(3):271-277. PubMed ID: 27813398
[TBL] [Abstract][Full Text] [Related]
8. Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12.
Ikeda S; Nakamura E; Narusawa K; Fukuda F; Matsumoto H; Nakai K; Sakata T; Yoshioka T; Fujino Y; Sakai A;
J Bone Miner Metab; 2020 Jan; 38(1):44-53. PubMed ID: 31297652
[TBL] [Abstract][Full Text] [Related]
9. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
11. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
13. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture.
Yoo JI; Ha YC; Ryu HJ; Chang GW; Lee YK; Yoo MJ; Koo KH
J Clin Endocrinol Metab; 2017 Feb; 102(2):560-565. PubMed ID: 27880077
[TBL] [Abstract][Full Text] [Related]
15. Is Bone Nonunion, Vertebral Deformity, or Spinopelvic Malalignment the Best Therapeutic Target for Amelioration of Low Back Pain After Osteoporotic Vertebral Fracture?
Iwata A; Kanayama M; Oha F; Shimamura Y; Hashimoto T; Takahata M; Iwasaki N
Spine (Phila Pa 1976); 2020 Jul; 45(13):E760-E767. PubMed ID: 32049935
[TBL] [Abstract][Full Text] [Related]
16. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
17. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
Doria C; Leali PT; Solla F; Maestretti G; Balsano M; Scarpa RM
Clin Cases Miner Bone Metab; 2016; 13(3):195-199. PubMed ID: 28228781
[TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical symptoms of osteoporotic vertebral fracture with intravertebral cleft and radiographic findings.
Nakamae T; Fujimoto Y; Yamada K; Hiramatsu T; Hashimoto T; Olmarker K; Adachi N
J Orthop Sci; 2017 Mar; 22(2):201-206. PubMed ID: 28081928
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.
Piriyakhuntorn P; Tantiworawit A; Phimphilai M; Srichairatanakool S; Teeyasoontranon W; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
Front Endocrinol (Lausanne); 2023; 14():1178761. PubMed ID: 37251676
[TBL] [Abstract][Full Text] [Related]
20. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]